Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Assets Average (2016 - 2025)

Sangamo Therapeutics has reported Assets Average over the past 15 years, most recently at $74.2 million for Q4 2025.

  • Quarterly results put Assets Average at $74.2 million for Q4 2025, down 30.3% from a year ago — trailing twelve months through Dec 2025 was $74.2 million (down 30.3% YoY), and the annual figure for FY2025 was $80.7 million, down 39.55%.
  • Assets Average for Q4 2025 was $74.2 million at Sangamo Therapeutics, down from $93.1 million in the prior quarter.
  • Over the last five years, Assets Average for SGMO hit a ceiling of $907.8 million in Q1 2021 and a floor of $74.2 million in Q4 2025.
  • Median Assets Average over the past 5 years was $327.6 million (2023), compared with a mean of $399.6 million.
  • Biggest five-year swings in Assets Average: surged 48.61% in 2021 and later tumbled 71.01% in 2024.
  • Sangamo Therapeutics' Assets Average stood at $747.2 million in 2021, then dropped by 22.61% to $578.2 million in 2022, then crashed by 66.71% to $192.5 million in 2023, then plummeted by 44.7% to $106.4 million in 2024, then tumbled by 30.3% to $74.2 million in 2025.
  • The last three reported values for Assets Average were $74.2 million (Q4 2025), $93.1 million (Q3 2025), and $91.9 million (Q2 2025) per Business Quant data.